Meng Yu-Qing, Cui Xun, Li Siqi, Jin Cheng-Hua
Key Laboratory of Natural Resources of Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, Jilin, 133002, China.
Department of Physiology, School of Medicinal Sciences, Yanbian University, Yanji, Jilin, 133002, China.
Chem Biodivers. 2024 Dec;21(12):e202401078. doi: 10.1002/cbdv.202401078. Epub 2024 Oct 26.
Coronary heart disease, hypertension, myocarditis, and valvular disease cause myocardial fibrosis, leading to heart enlargement, heart failure, heart rate failure, arrhythmia, and premature ventricular beat, even defibrillation can increase the risk of sudden death. Although cardiac fibrosis is common and widespread, there are still no effective drugs to provide adequate clinical intervention for cardiac fibrosis. In this review article, we classify the compounds for treating cardiac fibrosis into natural products, synthetic compounds, and patent drugs according to their sources. Additionally, the structures, activities and signaling pathways of these compounds are discussed. This review provides insight and could provide a reference for the design of new anti-cardiac fibrosis compounds and the new use of older drugs.
冠心病、高血压、心肌炎和瓣膜病会导致心肌纤维化,进而引起心脏扩大、心力衰竭、心率衰竭、心律失常和室性早搏,甚至除颤也会增加猝死风险。尽管心脏纤维化很常见且广泛存在,但目前仍没有有效的药物能对心脏纤维化进行充分的临床干预。在这篇综述文章中,我们根据来源将治疗心脏纤维化的化合物分为天然产物、合成化合物和专利药物。此外,还讨论了这些化合物的结构、活性和信号通路。本综述提供了见解,并可为新型抗心脏纤维化化合物的设计以及老药的新用途提供参考。